to be leveraged to rapidly initiate clinical studies in a highly cost-effective manner.
CLINICAL TRIALS & SPECIAL ACCESS TO CELL THERAPIES PREREGISTRATION IN AUSTRALIA
Clinical trials of unapproved therapeutic goods in Australia are conducted under either the clinical trial notification (CTN) or clinical trial exemption (CTX) scheme, depending on the perceived risk profile and novelty of the therapy. The vast majority of clinical trials in Australia are performed using the CTN scheme, which requires a scientific and ethical review by the applicable human research ethics committee(s) (HREC(s)) only, with notification to, but not review by, the regulator, the Therapeutic Goods Administration (TGA). The HREC review typically takes 8 to 12 weeks, with a CTN notification period to the TGA of approximately 10 days. For such an application, only central trial documents are needed i.e., the clinical trial protocol, Investigator's Brochure and patient information and consent form, with an option of an independent toxicology report to support nonclinical safety data. Submission of these documents can be to individual HRECs, or, where required, through single submission to multiple HRECs via a Human Research Ethics Application (HREA). This capitalises on the National Mutual Acceptance (NMA) of scientific and ethical review of multi-centre clinical research in all Australian jurisdictions, except Tasmania and the Northern Territory. Currently, fees are typically around AU$6000 for HREC review, plus AU$350 for TGA notification.
This abbreviated application requirement, absence of a formal regulatory review, and short assessment timeline make the CTN an attractive option for Sponsors seeking rapid clinical trial initiation, with little resource requirement for document preparation relative to other jurisdictions. Indeed, the success of the CTN is demonstrated by increasing traction among Asian countries for a similar, aligned system. Already adopted in Japan, the CTN system is under consideration in South Korea, where it is intended to recognize authorization from other regulatory agencies, and Singapore is transitioning to a risk-based CTN scheme for some trials as of 2018.
In contrast to the CTN, the CTX Scheme requires submission of a dossier in Common Technical Document (CTD) format for review by the TGA, similar to a US IND or European CTA. In this case, the evaluation process typically takes 30 to 50 working days plus clock-stops, with a fee of AU$21,100. Although accepted by all Australian clinical trial sites, an HREC approval must also accompany CTX approval from the TGA.
The choice of whether to follow the CTN or the CTX scheme lies initially with the Sponsor and then with the HREC, and depends on the biological classification (see below) and the scientific expertise required for assessment (Figure 1) .
Access to unapproved therapeutic products may be required outside of a formal research setting. In recognition of this, the TGA Under the Therapeutic Goods Regulations 1990 (amended 2018), a 'biological medicine' may also be produced through recombinant technology or biotechnology. Biologicals are defined in four classes (Table 1) .
Importantly, a CTX is required for all first in human (FIH) trials with a Class 4 biological product (unless a trial has been authorized for an equivalent indication in the EU, US, Canada, Singapore or Switzerland). Where Class 4 biologicals have existing clinical trial approval in other jurisdictions, or existing clinical data, and for all other classes of biologicals, a more rapid CTN approval via an HREC is appropriate.
At present, most autologous human cell therapies (HCTs), unless blood or blood components or substantially manipulated, can be supplied without approval by the TGA [4] . To meet this exemption, the donor starting material must be collected from a patient under the clinical care and treatment of a medical practitioner, and the same medical practitioner must manufacture (or oversee manufacture) and perform/ supervise the use of the autologous HCT for treatment of a single indication in a single course of treatment for the same patient.
From July 2018, the BRF is expected to be revised such that regulation of autologous HCTs will be based on risk. The following changes are expected for implementation: The onus is on the Sponsor to ensure that the two conditions to qualify as an Exempt Dealing are met, as the OGTR has no formal Exempt Dealing application or evaluation process. An Institutional Biosafety Committee (IBC), either independent or associated with the clinical trial site, should be notified that the product is considered an Exempt Dealing. The Sponsor should request that the IBC provide their own interpretation with justifications in a letter to be included in the HREC application to facilitate the HREC's understanding during review of the clinical trial documentation.
Should a cell therapy product meet the definition of a GMO under the Act and associated Regulations (2001) 
TECHNICAL EXPECTATIONS
In keeping with its recognition of clinical trial authorisations from certain overseas regulators, the TGA seeks to closely align expectations for development of novel therapeutic products with those of comparable international counterparts. As a result, technical data requirements for Australian prescription medicine registration applications (analogous to a Marketing Authorisation Application/ Biological Licence Application and New Drug Application) or post authorisation variations overlap with or incorporate the technical aspects of relevant European Union (EU) and ICH guidelines. To ensure relevance and applicability to the Australian market, adoption of EU or ICH guidelines follows extensive internal and external consultation. All EU and ICH guidelines adopted in Australia are listed online [8]. Adopted guidelines are not mandated by Australian legislative requirements, with primary governance defined by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, and supported by additional Therapeutic Goods Orders, Notices and Determinations. Nonetheless, guidance to Sponsors contained within adopted guidelines should be followed, and any deviation from an applicable guideline relevant to an application must be justified.
IMPORTATION & GMP REQUIREMENTS
Importation of cell therapies into Australia requires an import permit issued by the Australian Quarantine and Inspection Service (AQIS). An AQIS permit application is completed through the Biosecurity Import Conditions System (BICON) web-based portal and takes 20 working days to process. Australia follows Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidance. Therefore, investigational products in early clinical development should be manufactured to 'GMP-like' standards, defined as a manufacturing process where the quality of material produced is equivalent to that manufactured to GMP standards but where the manufacturing facility itself does not necessarily need GMP certification. Practically, GMP-like investigational products may lack the same extent of process and procedure validation required for GMP manufacture. Nonetheless, materials of sufficient quality are used and suitable testing is performed (according to ICH, EMA or FDA guidelines), to ensure the production of a safe and effective investigational product with suitable stability for the clinical trial. GMP compliance may not be subject to inspection until an application for product registration, and there seems to be limited evidence of GMP licensure being mandated by the TGA during clinical trials, but safety reporting to the TGA during the trial will be expected according to GCP. Given this GCP expectation, trial data obtained from studies in Australia, with fast-track start-up given 'GMPlike' manufacturing requirements, is considered valid for subsequent European and US applications.
It should be noted that whereas a full Module 3 (Quality) and Module 2.3 (Quality Overall Summary) will be required in CTD format for CTX applications, only details of the pharmaceutical and chemical properties, formulation, stability and shelf-life, stated in the Investigator's Brochure, are required for a CTN.
COMPARING CLINICAL TRIAL TIMELINES BETWEEN AUSTRALIA & THE US/EU
Clinical trial timelines, including procedures and requirements, are outlined in Table 2 . Australia provides a number of benefits to cell therapy manufacturers, encouraging rapid trial start up.
RESEARCH AND DEVELOPMENT (R&D) TAX INCENTIVE
In addition to an abbreviated regulatory pathway under the CTN which can lessen resource burden for document preparation and expedite trial initiation, the Australian government currently offers the R&D Tax Incentive to eligible parties. The incentive, which is intended to stimulate and support innovation for Australian businesses, provides a targeted tax offset to encourage companies to engage in R&D. If medicinal product developmental activities are performed within Australia by an Australian business, the cost of the activities should be eligible for a R&D tax rebate (43.5% at the time of publication). Specifically, the commercial entity claiming the rebate is required to be incorporated under a foreign law, to have at least AU$20,000 of eligible expenditure on eligible R&D activities, and to be both a resident of a country with which Australia has a double tax agreement that includes a definition of 'permanent establishment' and carrying on business in Australia through a permanent establishment as defined in the double tax agreement.
The scheme enables a 43.5% refundable tax offset for companies if they have an aggregate annual turnover of less than AU$20 million and a non-refundable 38.5% tax offset for all other eligible companies. For foreign entities that establish a presence in Australia and meet other eligibility criteria, the scheme affords conduct of highly cost-effective clinical trials.
CLINICAL EXPERIENCE IN AUSTRALIA WITH CELL BASED THERAPIES
Given the attractive benefits which include an abbreviated regulatory pathway, the 'GMP-like' manufacturing requirement and R&D cashback incentives, how experienced is the Australian clinical environment with cell based therapies and advanced therapy medicinal products?
For confidence in GCP trial conduct, each Australian state capital (Adelaide, Brisbane, Melbourne, Perth, Sydney) accommodates a dedicated Phase I unit. Furthermore, dedicated cell therapy facilities, such as the Victorian Comprehensive Cancer Centre (VCCC) at the Peter MacCallum Cancer Centre in Melbourne, enable on site integrated cell processing capabilities with patient access. This has
